Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 14/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metesind SCHEMBL1229424 | 0.87 | TYMS (0.76) | TYMSGAAATMALDH1A1 | |
| Metesind SCHEMBL6760900 | 0.87 | TYMS (0.75) | TYMSGAAATMALDH1A1 | |
| SCHEMBL8168880 | 0.76 | TYMS (0.61) | TYMSATMALDH1A1 | |
| SCHEMBL9055601 | 0.75 | TYMS (1.00) | TYMS | |
| SCHEMBL9087202 | 0.71 | TYMS (1.00) | TYMS | |
| SCHEMBL9056927 | 0.69 | TYMS (1.00) | TYMS | |
| SCHEMBL8168877 | 0.68 | TDP1 (0.52) | TYMSGAAALDH1A1 | |
| SCHEMBL9587845 | 0.67 | DHFR (0.52) | TYMSGAAALDH1A1 | |
| SCHEMBL15231957 | 0.67 | POLB (0.67) | GAAALDH1A1 | |
| SCHEMBL17117499 | 0.66 | GAA (0.59) | GAAATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | claimed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | claimed |
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | HALOZYME, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12371685-B2 | PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof | HALOZYME, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250222078-A1 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HALOZYME, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250197835-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HALOZYME, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250197833-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HALOZYME, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250197836-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HALOZYME, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250197832-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HALOZYME, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250197834-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HALOZYME, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250154488-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HALOZYME, INC. | 2025-05-15 | — | — | US | disclosed |
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | HALOZYME, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230022205-A1 | CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY | CALIDI BIOTHERAPEUTICS (NEVADA), INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220372151-A1 | COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR | HALOZYME, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11505782-B2 | Cell-based vehicles for potentiation of viral therapy | CALIDI BIOTHERAPEUTICS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11414489-B2 | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor | HALOZYME, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371685-B2 | PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof | MMP20, HM13, PHF20 | TYMS 4419/4885GAA 399/4885ATM 4848/4885 |
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | PREP, HM13, MMP20 | TYMS 4453/4885GAA 1395/4885ATM 4846/4885 |
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | ABCB1, ABCC1, DPYD | TYMS 267/4885GAA 711/4885ATM 1882/4885 |
| US-20250197836-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | MMP20, HM13, PHF20 | TYMS 4090/4885GAA 264/4885ATM 4856/4885 |
| US-20250197832-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | MMP20, HM13, PHF20 | TYMS 4090/4885GAA 264/4885ATM 4856/4885 |
| US-11414489-B2 | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor | CD44, ENGASE, HPSE | TYMS 436/4885GAA 111/4885ATM 1167/4885 |
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | ADA, CDA, ADAR | TYMS 361/4885GAA 85/4885ATM 1774/4885 |
| US-20250197834-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | MMP20, HM13, PHF20 | TYMS 4090/4885GAA 264/4885ATM 4856/4885 |
| US-20250222078-A1 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | CD44, HPSE, ENGASE | TYMS 1138/4885GAA 12/4885ATM 4056/4885 |
| US-20220372151-A1 | COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR | CD44, ENGASE, HPSE | TYMS 465/4885GAA 115/4885ATM 1176/4885 |
| US-20250154488-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | MMP20, HM13, PHF20 | TYMS 4090/4885GAA 264/4885ATM 4856/4885 |
| US-20250197833-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | MMP20, HM13, PHF20 | TYMS 4090/4885GAA 264/4885ATM 4856/4885 |
| US-20250197835-A1 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | MMP20, HM13, PHF20 | TYMS 4090/4885GAA 264/4885ATM 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.